Hiromasa Tanaka
Papers
2
Total Citations
320
H-Index
2
About
Hiromasa Tanaka is a leading figure in the emerging field of plasma medicine, where his work bridges physics and oncology to develop novel cancer therapies. His primary research focuses on the application of nonequilibrium atmospheric pressure plasma (NEAPP) for selective cancer cell treatment. In his landmark 2012 study, cited over 300 times, Tanaka demonstrated that NEAPP can selectively induce apoptosis in ovarian cancer cells while sparing healthy fibroblasts, a breakthrough that highlighted the potential for targeted, non-thermal plasma-based cancer therapies. This foundational work has positioned him as a pioneer in understanding how reactive species generated by plasma can trigger programmed cell death in malignant cells. Beyond this, Tanaka’s research explores the molecular mechanisms of plasma-induced apoptosis and the development of plasma devices for clinical applications. His contributions have not only advanced the fundamental science of plasma–cell interactions but have also paved the way for future therapeutic strategies in oncology, making him a key figure in translating physical plasma technologies into biomedical solutions.
Research Focus
Key Achievements
Top Papers
- 1
- 2